| 摘要 |
The present invention relates to the use of adenosine level affecting-compounds selected from the group comprising dipyridamole, mopidamol, dilazep, draflazine, 2,6-Bis(diethanolamino)-4,8-diheptamethyleneimino-pyrimido[5,4-d]pyrimidine, RA-642, adenosine, adenosine analogues, adenosine A 2(A) receptor agonists, inhibitors of adenosine kinase, activators of ecto-5'-nucleotidase and/or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the therapeutic or prophylactic treatment and/or diagnosis of clinical conditions resulting from a deficit of endothelial progenitor cells.
|
